文献速递造血干细胞移植与细胞治疗

抗GD2抗体地努图希单抗β联合低剂量白细胞介素-2用于复发神经母细胞瘤单倍体造血干细胞移植后:多中心I/II期试验

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
PubMed 文献 · J Clin Oncol · 2023-02-28

该多中心I/II期试验评估复发高危神经母细胞瘤患者接受T/B细胞去除的单倍体造血干细胞移植后,使用地努图希单抗β联合皮下白细胞介素-2的安全性与疗效。68例符合免疫治疗条件,37例(54.4%)达到主要终点,5年无事件生存率和总生存率分别为43%和53%。

要点

  • 地努图希单抗β联合皮下白细胞介素-2在单倍体移植后可行,诱导移植物抗宿主病风险低。
  • 37例(54.4%)达到主要终点,中位观察7.8年,5年无事件生存率43%,总生存率53%。
  • 移植后免疫治疗前完全缓解或部分缓解者5年无事件生存率显著优于无反应/混合反应/进展者。

核心结论

  • 复发高危神经母细胞瘤患者单倍体移植后使用地努图希单抗β治疗可行,诱导移植物抗宿主病风险低,并带来长期缓解,可能归因于供者来源效应细胞抗神经母细胞瘤活性增强。

研究设计与样本

  • 多中心I/II期试验,纳入1-21岁复发高危神经母细胞瘤患者,接受T/B细胞去除的单倍体造血干细胞移植,随后给予地努图希单抗β和皮下白细胞介素-2。
  • 共筛查70例,68例符合免疫治疗条件。

主要发现

  • 地努图希单抗β中位周期数为6(范围1-9),皮下白细胞介素-2中位周期数为3(范围1-6)。
  • 主要终点达成率为54.4%(37例),中位观察时间7.8年。
  • 5年无事件生存率为43%(95%CI 31-55),5年总生存率为53%(95%CI 41-65)。
  • 免疫治疗前完全缓解者5年无事件生存率为52%(95%CI 31-69),部分缓解者为44%(95%CI 27-60),无反应/混合反应/进展者为13%(95%CI 1-42),完全缓解或部分缓解者显著优于无反应/混合反应/进展者(P=0.026)。
  • 单倍体移植后有疾病证据的43例中,总缓解率为51%(22例),其中15例(35%)达到完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of natural killer cells and their activation by the anti-GD2 antibody dinutuximab beta (DB). This phase I/II trial assessed safety, feasibility, and outcomes of immunotherapy with DB plus subcutaneous interleukin-2 (scIL2) after haplo-SCT in patients with rHR-NB. METHODS: Patients age 1-21 years underwent T-/B-cell-depleted haplo-SCT followed by DB and scIL2. The primary end point 'success of treatment' encompassed patients receiving six cycles, being alive 180 days after end of trial treatment without progressive disease, unacceptable toxicity, acute graft-versus-host-disease (GvHD) ≥grade 3, or extensive chronic GvHD. RESULTS: Seventy patients were screened, and 68 were eligible for immunotherapy. Median number of DB cycles was 6 (range, 1-9). Median number of scIL2 cycles was 3 (1-6). The primary end point was met by 37 patients (54.4%). Median observation time was 7.8 years. Five-year event-free survival (EFS) and overall survival from start of trial treatment were 43% (95% CI, 31 to 55) and 53% (95% CI, 41 to 65), respectively. Five-year EFS among patients in complete remission (CR; 52%; 95% CI, 31 to 69) or partial remission (44%; 95% CI, 27 to 60) before immunotherapy were significantly better compared with patients with nonresponse/mixed response/progressive disease (13%; 95% CI, 1 to 42; P = .026). Overall response rate in 43 patients with evidence of disease after haplo-SCT was 51% (22 patients), with 15 achieving CR (35%). Two patients developed GvHD grade 2 and 3 each. No unexpected adverse events occurred. CONCLUSION: DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GvHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity by donor-derived effector cells.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Flaadt T, Ladenstein RL, Ebinger M, et al. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023. PMID: 36854071. doi:10.1200/JCO.22.01630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。